NCT07105033 Development and Pilot Trial of Focused ACT (FACT) for Patients With Advanced Cancer
| NCT ID | NCT07105033 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Advanced Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-07-21 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2025-07-21 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To learn about the effects of an intervention program called Focused Acceptance and Commitment Therapy (FACT) on the level of anxiety patients diagnosed with cancer feel about death. To learn if an intervention program called Focused Acceptance and Commitment Therapy (FACT), designed to help reduce death-related anxiety, is effective and acceptable to patients diagnosed with advanced cancer.
Eligibility Criteria
Inclusion Criteria: * Adult cancer patients diagnosed with advanced cancer (solid tumor and hematologic) * Progressed past at least one line of palliative systemic cancer therapy * Patient followed by Supportive Care Outpatient Service * English speaking * Able to provide written informed consent * Willing to participate in a stress and coping program * Willing to identify 1-2 important areas of life they might like to discuss with a counselor * Moderate levels of death anxiety on DADDS (\>=25, on 0-75 scale) * Access to technology to support institutionally approved video-conferencing platform of Zoom Exclusion Criteria: * ECOG performance status \>=3 "capable of only limited selfcare; confined to bed or chair more than 50% of waking hours" * Currently participating in regular psychotherapy (patient defined) * Documented out of hospital DNR (do not resuscitate) orders * Presence of active suicidal ideation or need for a higher level of care (as determined by Supportive Care physician or licensed mental health clinician).
Contact & Investigator
Juliet Kroll, BA,PHD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT07105033 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07105033 currently recruiting?
Yes, NCT07105033 is actively recruiting participants. Contact the research team at jlkroll@mdanderson.org for enrollment information.
Where is the NCT07105033 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT07105033 clinical trial?
NCT07105033 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Juliet Kroll, BA,PHD at M.D. Anderson Cancer Center. The trial plans to enroll 70 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.